Background: This is the first retrospective report of pregnancy outcomes after exposure to adalimumab treatment in Japan. Methods: Using the AbbVie safety database, we analyzed pregnancy outcome data from patients who received adalimumab treatment from April 16, 2008, to May 15, 2017. Results: Data were extracted retrospectively for 74 pregnancies in 73 patients. More than half of the patients included in the study received adalimumab for the treatment of Crohn's disease (37.8%) or ulcerative colitis (20.3%), while 9.5% received adalimumab for rheumatoid arthritis. Of the 53 pregnancies with available outcome data, 45 newborns (45/53 [84.9%]) were delivered. Of these births, 30 were full-term, 2 were preterm, and 13 were unknown. Apgar scores were available for 11 of the 16 newborns whose mothers were exposed to adalimumab in the third trimester; all scores were within the normal range. Low birth weight was observed in 5 infants out of the 30 full-term deliveries. There were also 5 miscarriages (5/53 [9.4%]), 2 induced abortions (2/53 [3.8%]), and 1 stillbirth (1/53 [1.9%]). Eight maternal adverse events were observed in 5 pregnancies; no serious adverse events occurred. Conclusion: Although safety concerns were inconclusive, these data do not report additional risk to pregnancy outcomes with adalimumab exposure.
Introduction
Immune-mediated diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA), frequently affect women of reproductive age [1] . During pregnancy, hormonal changes occur, including an increase in estrogen levels that mainly stimulates T-helper cell (Th) 2-mediated immunological responses and suppresses Th1 cytokines [2] . Thus, patients with Th2-mediated disease, such as ulcerative colitis (UC) and other immune-mediated diseases, tend to experience flares in their disease activity during this period [3, 4] . Also, it is reported that poor disease control and high disease activity during pregnancy can affect the outcome of that pregnancy [5] . Therefore, adequate and optimal treatment of immune-mediated diseases during pregnancy is essential.
These diseases are often treated with biologic agents that target tumor necrosis factor-α (TNF-α), the key inflammatory cytokine produced by T cells and macrophages; however, the understanding of the safety profile of TNF-α inhibitors during pregnancy is still evolving [1] .
Guidelines in Japan for the use of TNF-α inhibitors in the treatment of RA, ankylosing spondylitis, and noninfectious uveitis specifically recognize the lack of established safety data in fetuses and infants. According to these guidelines, if unintentional fetal exposure is confirmed, TNF-α inhibitor therapy should be stopped immediately and appropriate follow-up should be conducted [6] [7] [8] [9] . In IBD, including UC and Crohn's disease (CD), specific recommendations for the use of these medications during pregnancy have not been issued in Japan [10] . According to the Japanese Dermatological Association, biologic agents should be avoided in patients with psoriasis during pregnancy because of insufficient evidence for their safety [11] . In Western countries, the use of TNF-α inhibitors during pregnancy has been better studied. Thus far, a question still remains that the increased immunoglobulin G (IgG) antibodies themselves, or any other effect caused by the use of TNF-α inhibitors during the third trimester adversely affects the outcome of pregnancy. According to the European League Against Rheumatism (EULAR) task force, exposure to these medications during the first and second trimesters is considered reasonably safe in patients with inflammatory rheumatic diseases. Therefore, the continuation of TNF-α inhibitors during the first trimester of pregnancy can be considered in these patients [12] . Furthermore, the European Crohn's and Colitis Organization (ECCO) considers the use of TNF-α inhibitors to be controversial and recommends the discontinuation of these agents around gestational weeks 24-26 after giving due consideration to both maternal disease activity and drug placental transfer [13] . Nevertheless, due to lack of clear evidence on the safety of these agents, the US Food and Drug Administration classifies TNF-α inhibitors, including adalimumab, as pregnancy category B (no adequate and well-controlled studies in humans; however, there is no evidence of harm in animal studies) [14] .
Adalimumab is a human anti-TNF-α monoclonal antibody that was approved in Japan in April 2008 for the treatment of patients with RA and was subsequently approved for use in patients with psoriasis, psoriasis vulgaris, psoriatic arthritis, ankylosing spondylitis, CD, juvenile idiopathic arthritis (JIA), intestinal Behçet's disease, UC, and noninfectious uveitis [15] .
The North American Adalimumab Pregnancy Exposure Registry was created to monitor pregnancy outcomes in patients with RA. A study based on data from this registry showed that the frequency and relative risk of major birth defects were similar among patients exposed to adalimumab, patients not exposed to adalimumab, and healthy women without RA. Moreover, the study did not identify any patterns of specific birth defects in the cohort exposed to adalimumab [16] . In Japan, there are limited data related to the safety of adalimumab exposure during pregnancy, with the most relevant evidence being in the form of case reports or small studies [17] [18] [19] [20] . This is a retrospective report of pregnancy outcomes following exposure to adalimumab treatment in Japan.
Methods
After the approval of adalimumab in Japan in April 2008, safety reports, including pregnancy reports in patients receiving adalimumab treatment, obtained from several sources, including postmarketing surveillance reports, spontaneous reports, reports from literature, and others, were entered into AbbVie's safety database. In this study, we searched the database for data from patients with confirmed pregnancies that occurred while being treated with adalimumab. All available pregnancy-associated data reported between April 16, 2008 , and May 15, 2017, were collected, including details of treatment with adalimumab, pregnancy outcomes, and maternal adverse events. The causal relationship of an adverse event with adalimumab was judged by AbbVie, without any downgrading of the causality assessments given by the reporting physicians. Gestational age and delivery date were used to estimate the timing and duration of exposure to adalimumab during and before pregnancy. The outcome analysis set comprised patients in whom the outcome of pregnancy was available ( Fig. 1) .
Results

Patient Demographics and Characteristics
Data were extracted for 74 pregnancies occurring in 73 patients (1 patient had 2 pregnancies). Outcome data were available for 53 pregnancies (outcome analysis set; Fig. 1 formation. Among these pregnancies, adalimumab was administered for the required indication when the pregnancy was confirmed in 58 pregnancies and was initiated during Weeks 3, 7, and 11 in 3 pregnancies. No information was available regarding adalimumab administration in 13 pregnancies. A total of 25 pregnancies were exposed in the second trimester and 17 were exposed in the third trimester (Table 1) . At least 20 patients discontinued adalimumab therapy during pregnancy, out of which 6 patients discontinued adalimumab in the first trimester. Of the 45 live births, 23 were vaginal deliveries, 14 were cesarean deliveries, and 8 were unknown.
Live Births
Among the 53 pregnancies for which pregnancy outcome data were available, a total of 45 infants (84.9%) were delivered by 45 patients. Of these deliveries, 30 were full-term (≥37 weeks), 2 were preterm (< 37 weeks), and 13 were unknown. Of the 30 full-term deliveries, 25 (83.3%) newborns weighed ≥2,500 g and 5 (16.7%) newborns weighed < 2,500 g (1,878-2,484 g; Fig. 1 ).
Fetal and Neonatal Adverse Outcomes
Of the 53 pregnancies for which outcome data were available, there were 5 miscarriages (9.4%), 2 induced abortions (3.8%), and 1 stillbirth (1.9%; Table 2 ). The reason for the 2 induced abortions was unknown. Of the 5 miscarriages, data were available for 4 cases: adalimumab was continued after a miscarriage that occurred at Week 9 with 9 weeks of adalimumab exposure in a 31-year-old CD patient; adalimumab was continued after a miscarriage at Week 8 with 8 weeks of adalimumab exposure in a 29-year-old patient with intestinal Behçet's disease; adalimumab was continued after a miscarriage at Week 8 with 8 weeks of adalimumab exposure in a 32-year-old patient with psoriasis; and adalimumab was stopped after a miscarriage at Week 8 with 6 weeks of adalimumab exposure in a 31-year-old CD patient. None of these patients reported any maternal adverse events during their pregnancies. Adalimumab was continued until stillbirth that occurred at Week 35 in a 34-year-old patient whose pregnancy was identified approximately 6 months after adalimumab was initiated for the treatment of UC. The cause of the stillbirth was unknown. The patient experienced symptoms of threatened premature labor at Weeks 34 and 35, with stillbirth confirmed at Week 35.
Other fetal and neonatal adverse outcomes determined by the attending physicians were reported in 4 patients. All the patients had received adalimumab therapy at least during the first trimester. In one instance, a CD patient treated with adalimumab for the entire 38-week gestational period gave birth to a low-birth-weight infant with patent ductus arteriosus. A second CD patient treated with adalimumab for an unspecified time period during pregnancy gave birth to a normal-weight, full-term infant with abnormal fetal heart rate. In the third case, a UC patient treated with adalimumab for the first 11 weeks of her pregnancy went into preterm labor at 33 weeks, giving birth to an infant of extremely low birth weight (900 g; no detailed information available). Finally, a fourth patient treated with adalimumab for JIA for 32 weeks of her pregnancy gave birth to a normal-weight, full-term infant in whom non-reassuring fetal status was detected at the time of delivery by the attending physician (details unavailable); however, no congenital abnormalities were observed at birth. Overall, no congenital abnormalities were observed in any of the pregnancies reported here, including those exposed to adalimumab during the first trimester.
Pregnancy Outcomes in Patients Exposed to Adalimumab in the Third Trimester
Given the concern that IgG can be transported through the placenta during the third trimester [21] , outcomes for adalimumab administration during the third trimester were also evaluated.
Of the 17 pregnancies that involved exposure to adalimumab in the third trimester, all had received adalimumab from the first trimester (14 before diagnosis of pregnancy and 3 initiated at Weeks 3, 7, and 11). Among them, 16 pregnancies progressed to full-term live births. Of these births, Apgar scores were available for 11 newborns, all of which were within the normal range (≥7) at 1 and 5 minutes. Birth weights ranged from 2,252 to 3,426 g in 15 newborns; 1 newborn had a birth weight of 1,878 g. One pregnancy resulted in stillbirth, as described in the previous section (Table 3) .
Maternal Adverse Events
A total of 8 maternal adverse events were reported in 5 pregnancies and classified as non-serious adverse events by the physician (Table 4 ). All the maternal adverse events occurred during pregnancy. These included viral upper respiratory tract infection in 1 CD patient with 38 weeks of adalimumab exposure; hematoma, positive rubella antibody (with a serum hemagglutination inhibition titer of 256), and anemia in 1 CD patient with 41 weeks of adalimumab exposure; fever in 1 UC patient with adalimumab exposure during the first 24 weeks of pregnancy; erythema in 1 RA patient with an unknown adalimumab exposure period; and gestational hypertension and herpes simplex in 1 psoriasis patient with 41 weeks of adalimumab exposure. No serious adverse events were reported.
Discussion
This is the first retrospective report from Japan describing pregnancy outcomes after exposure to adalimumab. Of the 74 pregnancies in this database, more than half (43, 58.1%) were prescribed to treat CD (28, 37.8%) or UC (15, 20.3%); 7 (9.5%) for RA; 7 (9.5%) for psoriasis; 4 (5.4%) for intestinal Behçet's disease; and 1 (1.4%) each for ankylosing spondylitis and JIA. The indications in 11 (14.9%) pregnancies were unknown. In general, patients with UC or CD tend to be affected at a relatively young age [22] , whereas patients with RA are typically older [23] . These disease-specific factors are likely responsible, at least in part, for the higher number of patients with UC and CD in our dataset.
A 2017 systematic review and meta-analysis reported similar outcomes between pregnant patients who were and who were not treated with TNF-α inhibitors, including those who were treated for RA, IBD, and various immune-mediated diseases [1] [1] . In addition, several reports have investigated the safety of TNF-α in- hibitor therapy during pregnancy. The Organization of Teratology Information Specialists (OTIS) investigators compared pregnant patients with RA exposed to adalimumab (n = 74) with those not exposed to adalimumab (n = 80) and with a healthy cohort of women (n = 219).
Results of the OTIS study showed that the proportions of live births (87.8 vs. 92.5 vs. 90.4%) and major birth defects (4.2 vs. 6.5 vs. 5.0%) were similar among patients with RA exposed to adalimumab, those not exposed to adalimumab, and healthy women unaffected by RA, respectively. The rate of preterm delivery was comparable between the group exposed to adalimumab and the group with RA not exposed to adalimumab (adjusted hazard ratio = 1.08, 95% CI 0.41-2.83). Overall, this analysis of the OTIS registry data did not identify any patterns of adverse pregnancy outcomes or defects during prenatal development associated with adalimumab exposure during pregnancy [16] . Another result from a Japanese study of pregnancy outcomes in IBD patients showed no relevant increase in premature births (5.9 vs. 6.9%), low birth weight (23.5 vs. 24.1%), median birth weight (2,844 vs. 2,920 g), and congenital anomalies (0 vs. 6.5%) among those who were treated with TNF-α inhibitors without an immunomodulator (n = 24) as compared to those who received neither TNF-α inhibitors nor immunomodulator (n = 31) [18] .
In our outcome population of 53 pregnancies, 45 (84.9%) pregnancies resulted in live birth and 5 (9.4%) resulted in miscarriage. These were numerically similar to the previous reports [1, 16, 18] . In addition, rates of low birth weight (21.9% [7/32] ) and preterm birth (6.3% [2/32] ) were similar to previous reports [1, 18] . Overall, due to the limited number of patients included in this study, as well as incomplete data in many cases, it is difficult to draw definitive conclusions.
Exposure in the first trimester was assessed in a study performed in 9 countries by the European Network of Teratology Information Services to evaluate the risk of major birth defects, miscarriage, preterm birth, and decreased birth weight after first-trimester exposure to TNF-α inhibitors (adalimumab, infliximab, etanercept, certolizumab pegol, and golimumab). Among the 495 exposed and 1,532 non-exposed pregnant patients, the risk of major birth defects (5.0 vs. 1.5%), preterm births (17.6 vs. 9.0%), and low birth weight (12.8 vs. 1.1%) was increased in the exposed cohort compared with the nonexposed cohort. The risk of miscarriage was not increased in the exposed cohort (9.3 vs. 7.9%). The authors concluded that the use of TNF-α inhibitors during pregnancy may carry a risk of adverse pregnancy outcomes of moderate clinical relevance (major birth defects and preterm birth: adalimumab [6%, 17.4%]; infliximab [4.5%, 16%]; etanercept [5.4%, 17 .9%], respectively) [24] . In contrast, in the current study, no fetal or neonatal congenital abnormalities and 4 (8.2%) miscarriages were observed in 49 pregnancies exposed to adalimumab during the first trimester.
It has been reported that placental transfer of IgG antibodies start to increase between 28 and 32 weeks [25] . Furthermore, both infliximab and adalimumab cross the placental barrier and can be detected in infants' sera at birth and up to 6 months after birth [12, 21] . Results from the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes (PIANO) study showed that the use of TNF-α inhibitors (infliximab, adalimumab, and certoli- zumab pegol) in the third trimester was not associated with an increase in preterm birth rates or maternal adverse events in the third trimester or the first 4 months postpartum [26, 27] . In our study, 17 pregnancies were exposed to adalimumab during the third trimester. Of these pregnancies, the outcomes of low birth weight and preterm birth were 23.5% (4/17) and 0.0% (0/17), respectively, as compared with overall pregnancies for which birth weight and gestational age were available (21.9% [7/32] and 6.3% [2/32], respectively). Also, in the PIANO study, it was shown that regardless of the disease activity during pregnancy, the use of thiopurines and anti-TNF agents was not associated with an increase in "any complication" [26] . The increased IBD activity was associated with adverse pregnancy outcomes; therefore, stabilization of disease and effective maintenance therapy throughout pregnancy are crucial [27, 28] . According to the ECCO statement, disease activity at conception or during pregnancy is linked to preterm birth and low birth weight. The ECCO statement therefore advises patients with IBD who wish to conceive to control disease activity prior to conception and maintain appropriate treatment regimens during pregnancy in order to reduce the risk of flares [13] . However, it is always necessary for the attending physician to take into consideration the risk-benefit balance of adalimumab use and share the information with individual patients.
One of the limitations of this study is the heterogeneity of the pregnant patients, including different underlying diseases (UC, CD, RA, and other conditions), periods of exposure, and durations of adalimumab administration, as potential bias for data analysis. Additionally, the diverse data sources with missing and incomplete data, as well as the relatively small number of pregnancy outcome reports, restricted our ability to statistically analyze and compare the results directly with published literature. Nevertheless, this study may provide some insight into the safety concerns of adalimumab because this is the first report on pregnancies in the Japanese population specifically focused on treatment with adalimumab.
Conclusion
The results of this study did not raise safety concerns in Japanese patients who were exposed to adalimumab during pregnancy; however, safety concerns are inconclusive due to the limitations of the study. Further studies are needed to establish proper and safe use of adalimumab during pregnancy.
